Connection

Co-Authors

This is a "connection" page, showing publications co-authored by John McCoy and Andy Goren.
Connection Strength

9.416
  1. Androgenetic alopecia may be associated with weaker COVID-19 T-cell immune response: An insight into a potential COVID-19 vaccine booster. Med Hypotheses. 2021 01; 146:110439.
    View in: PubMed
    Score: 0.916
  2. 5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia. J Eur Acad Dermatol Venereol. 2021 Apr; 35(4):e243-e246.
    View in: PubMed
    Score: 0.915
  3. Androgen receptor genetic variant predicts COVID-19 disease severity: a prospective longitudinal study of hospitalized COVID-19 male patients. J Eur Acad Dermatol Venereol. 2021 Jan; 35(1):e15-e17.
    View in: PubMed
    Score: 0.909
  4. Racial variations in COVID-19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti-androgens a potential treatment for COVID-19? J Cosmet Dermatol. 2020 Jul; 19(7):1542-1543.
    View in: PubMed
    Score: 0.887
  5. Low-dose daily aspirin reduces topical minoxidil efficacy in androgenetic alopecia patients. Dermatol Ther. 2018 11; 31(6):e12741.
    View in: PubMed
    Score: 0.789
  6. Social selection favours offspring prone to the development of androgenetic alopecia. J Biol Regul Homeost Agents. 2017 Oct-Dec; 31(4):1013-1016.
    View in: PubMed
    Score: 0.736
  7. Mechanism of action of minoxidil in the treatment of androgenetic alopecia is likely mediated by mitochondrial adenosine triphosphate synthase-induced stem cell differentiation. J Biol Regul Homeost Agents. 2017 Oct-Dec; 31(4):1049-1053.
    View in: PubMed
    Score: 0.736
  8. Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial. Front Med (Lausanne). 2021; 8:668698.
    View in: PubMed
    Score: 0.239
  9. Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial. Cureus. 2021 Feb 22; 13(2):e13492.
    View in: PubMed
    Score: 0.233
  10. Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial - Biochemical). Cureus. 2021 Feb 01; 13(2):e13047.
    View in: PubMed
    Score: 0.232
  11. The AndroCoV Clinical Scoring for COVID-19 Diagnosis: A Prompt, Feasible, Costless, and Highly Sensitive Diagnostic Tool for COVID-19 Based on a 1757-Patient Cohort. Cureus. 2021 Jan 07; 13(1):e12565.
    View in: PubMed
    Score: 0.231
  12. Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men. J Eur Acad Dermatol Venereol. 2021 Jan; 35(1):e13-e15.
    View in: PubMed
    Score: 0.227
  13. Male balding as a major risk factor for severe COVID-19: A possible role for targeting androgens and transmembrane protease serine 2 to protect vulnerable individuals. J Am Acad Dermatol. 2020 12; 83(6):e401-e402.
    View in: PubMed
    Score: 0.226
  14. Androgenetic alopecia in COVID-19: Compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign. J Am Acad Dermatol. 2020 12; 83(6):e453-e454.
    View in: PubMed
    Score: 0.224
  15. Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The "Gabrin sign". J Am Acad Dermatol. 2020 Aug; 83(2):680-682.
    View in: PubMed
    Score: 0.221
  16. Androgen sensitivity gateway to COVID-19 disease severity. Drug Dev Res. 2020 11; 81(7):771-776.
    View in: PubMed
    Score: 0.221
  17. A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain - A potential clue to the role of androgens in COVID-19 severity. J Cosmet Dermatol. 2020 Jul; 19(7):1545-1547.
    View in: PubMed
    Score: 0.220
  18. What does androgenetic alopecia have to do with COVID-19? An insight into a potential new therapy. Dermatol Ther. 2020 Jul; 33(4):e13365.
    View in: PubMed
    Score: 0.219
  19. Frontal pattern hair loss among Chinese women is frequently associated with ponytail hairstyle. Dermatol Ther. 2019 01; 32(1):e12784.
    View in: PubMed
    Score: 0.200
  20. The effect of topical minoxidil treatment on follicular sulfotransferase enzymatic activity. J Biol Regul Homeost Agents. 2018 Jul-Aug; 32(4):937-940.
    View in: PubMed
    Score: 0.194
  21. Styling without shedding: Novel topical formula reduces hair shedding by contracting the arrector pili muscle. Dermatol Ther. 2018 Jan; 31(1).
    View in: PubMed
    Score: 0.186
  22. Potential risk of developing herpes simplex encephalitis in patients treated with sildenafil following primary exposure to genital herpes. J Biol Regul Homeost Agents. 2017 Jul-Sep; 31(3):679-682.
    View in: PubMed
    Score: 0.181
  23. Minoxidil dose response study in female pattern hair loss patients determined to be non-responders to 5% topical minoxidil. J Biol Regul Homeost Agents. 2016 Oct-Dec; 30(4):1153-1155.
    View in: PubMed
    Score: 0.172
  24. Clinical symptoms of hyperandrogenic women diagnosed with COVID-19. J Eur Acad Dermatol Venereol. 2021 Feb; 35(2):e101-e104.
    View in: PubMed
    Score: 0.057
  25. Characterization of follicular minoxidil sulfotransferase activity in a cohort of pattern hair loss patients from the Indian Subcontinent. Dermatol Ther. 2018 11; 31(6):e12688.
    View in: PubMed
    Score: 0.049
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.